By Jennifer Chiou
New York, Sept. 22 - Cellerant Therapeutics, Inc. said it raised an additional $9 million in series B financing, raising the round's total to $25 million.
Novel Bioventures led investors, which included MPM Capital, Allen & Co. LLC, BD Ventures, CX Venture Group, Amgen founder George Rathmann, Camelot Ventures and Eminent Venture Capital Corp.
"Since the first close of our series B, Cellerant has made significant progress in advancing our purified hematopoietic stem cell infusion, CLT-001, toward the clinic for sickle cell disease," said president and chief executive officer Bruce Cohen in a news release.
"We expect that trial to be under way early next year. This series B funding will allow us to advance the CLT-001 sickle cell program as well as CLT-001 for the treatment of autoimmune diseases and our cell-based product CLT-008 for the treatment of radiation- and chemotherapy-induced neutropenia."
Based in San Carlos, Calif., Cellerant Therapeutics is a commercial-stage company developing products focused on the regulation of the hematopoietic system.
| Issuer: | Cellerant Therapeutics, Inc.
|
| Issue: | Preferred stock
|
| Amount: | $25 million total ($9 million in second closing)
|
| Round: | Series B
|
| Investors: | Novel Bioventures (lead), MPM Capital, Allen & Co. LLC, BD Ventures, CX Venture Group, George Rathmann, Camelot Ventures, Eminent Venture Capital Corp.
|
| Announcement date: | Sept. 22
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
